A possible increased risk of metamizole-associated neutropenia among COVID-19 patients.
Br J Clin Pharmacol
; 87(7): 2902-2906, 2021 07.
Article
in English
| MEDLINE | ID: covidwho-979671
ABSTRACT
Metamizole is commonly used as analgesic and antipyretic drug. The use of metamizole is prohibited in several countries due to its rare side effect of neutropenia and even agranulocytosis. Among the many symptoms of COVID-19, fever and diffuse pain predominant and therefore it can be assumed that metamizole may be widely used in the current epidemic period. So far, there have been no reports on the safety of metamizole in COVID-19 patients. We describe a series of 3 patients who developed severe neutropenia under metamizole treatment, raising a concern of a possible increased risk of this side effect among COVID-19 patients.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Neutropenia
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Br J Clin Pharmacol
Year:
2021
Document Type:
Article
Affiliation country:
Bcp.14703
Similar
MEDLINE
...
LILACS
LIS